US8481043B2
(en)
*
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
US20050191321A1
(en)
*
|
2004-02-26 |
2005-09-01 |
Allergan, Inc. |
Methods for treating headache
|
US20100266638A1
(en)
|
2004-02-26 |
2010-10-21 |
Allergan, Inc. |
Headache treatment method
|
US9078892B2
(en)
*
|
2004-02-26 |
2015-07-14 |
Allergan, Inc. |
Methods for treating pain and for treating a medication overuse disorder
|
EP1928484B1
(en)
*
|
2005-08-26 |
2010-02-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for treatment of headaches by administration of oxytocin
|
CA3065947C
(en)
|
2005-10-18 |
2023-03-07 |
National Jewish Health |
Conditionally immortalized long-term stem cells and methods of making and using such cells
|
ES2433251T5
(es)
|
2005-11-14 |
2020-03-13 |
Teva Pharmaceuticals Int Gmbh |
Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
|
US20080261893A1
(en)
*
|
2006-02-24 |
2008-10-23 |
Denise Barbut |
Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
|
WO2007120485A2
(en)
*
|
2006-03-30 |
2007-10-25 |
Cinergen, Llc |
Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
|
GB2438834A
(en)
|
2006-06-08 |
2007-12-12 |
Optinose As |
Intranasal protein administration
|
US7645767B2
(en)
*
|
2006-08-31 |
2010-01-12 |
Trinity Laboratories, Inc. |
Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
|
AU2008225100A1
(en)
*
|
2007-03-12 |
2008-09-18 |
Mayo Foundation For Medical Education And Research |
Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
|
CA2680613A1
(en)
*
|
2007-03-13 |
2008-09-18 |
National Jewish Medical And Research Center |
Methods for generation of antibodies
|
US9707274B2
(en)
|
2007-06-08 |
2017-07-18 |
Healthpartners Research & Education |
Methods for preventing and treating post-traumatic stress disorder (PTSD)
|
JP2011504163A
(ja)
*
|
2007-06-08 |
2011-02-03 |
ヘルスパートナーズ リサーチ ファウンデーション |
中枢神経系への治療化合物の標的化を高めるための薬学的組成物および方法
|
WO2009012376A1
(en)
*
|
2007-07-17 |
2009-01-22 |
The Ohio State University Research Foundation |
Compositions and methods for skin care
|
AU2008297899A1
(en)
*
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Use of human neuropeptide as a therapeutic agent
|
WO2009033489A2
(en)
*
|
2007-09-11 |
2009-03-19 |
Glostrup Hospital |
Selective pacl inhibitors for use in the treatment of migraine and headaches
|
EP2197462A2
(en)
*
|
2007-09-11 |
2010-06-23 |
Mondobiotech Laboratories AG |
Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent
|
JP2010539049A
(ja)
*
|
2007-09-11 |
2010-12-16 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
サイモシンβ4の単独、またはセクロピンAとの組合せでの、治療剤としてのペプチドの使用
|
AU2008303942A1
(en)
*
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of BFGF 1-24 and optionally (ARG 8) vasopressin to treat eg S. pneumoniae infection
|
NZ587292A
(en)
|
2008-03-04 |
2012-09-28 |
Pfizer Ltd |
Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
|
WO2009145956A2
(en)
*
|
2008-03-06 |
2009-12-03 |
The Trustees Of Columbia University In The City Of New York |
Uses of calpain inhibitors to inhibit inflammation
|
US20090246273A1
(en)
*
|
2008-03-27 |
2009-10-01 |
Al-Ghananeem Abeer M |
Ketorolac Sublingual Spray for the Treatment of Pain
|
US8986702B2
(en)
|
2008-05-16 |
2015-03-24 |
Taiga Biotechnologies, Inc. |
Antibodies and processes for preparing the same
|
FR2932483A1
(fr)
|
2008-06-13 |
2009-12-18 |
Cytomics Systems |
Composes utiles pour le traitement des cancers.
|
EP2746387A1
(en)
*
|
2008-07-21 |
2014-06-25 |
Taiga Biotechnologies, Inc. |
Differentiated anucleated cells and method for preparing the same
|
ES2681478T3
(es)
|
2008-08-28 |
2018-09-13 |
Taiga Biotechnologies, Inc. |
Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
|
WO2010029555A1
(en)
*
|
2008-09-12 |
2010-03-18 |
Slender Medical, Ltd. |
Virtual ultrasonic scissors
|
WO2010029441A2
(en)
*
|
2008-09-15 |
2010-03-18 |
Optinose As |
Nasal delivery
|
BRPI0919711A2
(pt)
*
|
2008-10-17 |
2015-12-08 |
Pharmacofore Inc |
composições farmacêuticas com liberação atenuada de opióides fenólicos
|
US8575309B2
(en)
|
2008-12-08 |
2013-11-05 |
Biousian Biosystems, Inc. |
Delta-opioid receptor selective analgesics
|
WO2010091198A1
(en)
|
2009-02-06 |
2010-08-12 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
AU2010249047A1
(en)
*
|
2009-05-13 |
2011-11-24 |
Protein Delivery Solutions, Llc |
Pharmaceutical system for trans-membrane delivery
|
EP2450036B1
(en)
|
2009-07-02 |
2016-06-15 |
Yamaguchi University |
Surface anesthetic agent
|
DK2459183T3
(en)
|
2009-07-27 |
2016-01-18 |
Nocicepta Llc |
Methods for the treatment of pain
|
FR2948809B1
(fr)
*
|
2009-07-31 |
2012-08-17 |
St Microelectronics Rousset |
Amplificateur de lecture faible puissance auto-minute
|
WO2011024113A1
(en)
|
2009-08-28 |
2011-03-03 |
Rinat Neuroscience Corporation |
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
|
WO2011031350A1
(en)
|
2009-09-08 |
2011-03-17 |
Pharmacofore, Inc. |
Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
|
US8622993B2
(en)
*
|
2009-12-18 |
2014-01-07 |
Healthpartners Research Foundation |
Device and method for delivering therapeutic substances to the maxillary sinus of a patient
|
AU2010330747B2
(en)
*
|
2009-12-18 |
2016-08-11 |
Achelios Therapeutics, Inc. |
Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
|
US20110184322A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Slender Medical Ltd. |
Method and device for treatment of keloids and hypertrophic scars using focused ultrasound
|
EP2542082B8
(en)
|
2010-03-03 |
2020-06-17 |
Neonc Technologies Inc. |
PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol
|
US20130089504A1
(en)
*
|
2010-04-21 |
2013-04-11 |
Signature Therapeutics, Inc. |
Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug
|
US9238020B2
(en)
|
2010-04-21 |
2016-01-19 |
Signature Therapeutics, Inc. |
Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
|
WO2011133348A1
(en)
|
2010-04-21 |
2011-10-27 |
Pharmacofore, Inc. |
Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
|
US20110262355A1
(en)
|
2010-04-21 |
2011-10-27 |
Jenkins Thomas E |
Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
|
US8617150B2
(en)
|
2010-05-14 |
2013-12-31 |
Liat Tsoref |
Reflectance-facilitated ultrasound treatment
|
US8956346B2
(en)
|
2010-05-14 |
2015-02-17 |
Rainbow Medical, Ltd. |
Reflectance-facilitated ultrasound treatment and monitoring
|
US9242122B2
(en)
|
2010-05-14 |
2016-01-26 |
Liat Tsoref |
Reflectance-facilitated ultrasound treatment and monitoring
|
CA2799733A1
(en)
|
2010-05-18 |
2011-11-24 |
Universite De Geneve |
New uses of oxytocin-like molecules and related methods
|
JP6005636B2
(ja)
*
|
2010-07-06 |
2016-10-12 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
Gaba類似体及びオピオイドを含む新規胃内滞留型剤形
|
EP3685835A1
(en)
|
2010-08-27 |
2020-07-29 |
Neonc Technologies, Inc. |
Pharmaceutical compositions comprising poh derivatives
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
GB201015371D0
(en)
*
|
2010-09-14 |
2010-10-27 |
Optinose As |
Nasal delivery
|
US8647661B1
(en)
*
|
2010-11-05 |
2014-02-11 |
Florida A&M University |
Surface modified multilayered nanostructures for dermal delivery
|
EP3130579B1
(en)
|
2010-12-17 |
2024-02-07 |
University of Southern California |
Conjugates of isoperillyl alcohol
|
ES2584634T3
(es)
|
2011-01-11 |
2016-09-28 |
Signature Therapeutics, Inc. |
Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
|
US8497237B2
(en)
|
2011-01-11 |
2013-07-30 |
Signature Therapeutics, Inc. |
Compositions comprising enzyme-cleavable oxycodone prodrug
|
US20120183580A1
(en)
*
|
2011-01-13 |
2012-07-19 |
Theralpha |
Analgesic Composition for Transbuccal Administration
|
US11523934B2
(en)
|
2011-02-04 |
2022-12-13 |
Seed Health, Inc. |
Method and system to facilitate the growth of desired bacteria in a human's mouth
|
US10687975B2
(en)
*
|
2011-02-04 |
2020-06-23 |
Joseph E. Kovarik |
Method and system to facilitate the growth of desired bacteria in a human's mouth
|
US11951139B2
(en)
|
2015-11-30 |
2024-04-09 |
Seed Health, Inc. |
Method and system for reducing the likelihood of osteoporosis
|
US11951140B2
(en)
|
2011-02-04 |
2024-04-09 |
Seed Health, Inc. |
Modulation of an individual's gut microbiome to address osteoporosis and bone disease
|
US11844720B2
(en)
|
2011-02-04 |
2023-12-19 |
Seed Health, Inc. |
Method and system to reduce the likelihood of dental caries and halitosis
|
BR112013022946A2
(pt)
|
2011-03-09 |
2017-07-18 |
Signature Therapeutics Inc |
pró-fármacos de agentes ativos com ligantes heterocíclocos
|
US8685916B2
(en)
|
2011-03-09 |
2014-04-01 |
Signature Therapeutics, Inc. |
Opioid prodrugs with heterocyclic linkers
|
US9949923B2
(en)
*
|
2011-03-15 |
2018-04-24 |
Optinose As |
Nasal delivery
|
LT2694049T
(lt)
|
2011-04-05 |
2018-12-27 |
GrĆ¼nenthal GmbH |
Tapentadolis, skirtas skausmo perėjimo į lėtinį prevencijai
|
PL2694050T3
(pl)
*
|
2011-04-05 |
2020-03-31 |
Grünenthal GmbH |
Tapentadol do stosowania w leczeniu bólu związanego z nerwobólami nerwu trójdzielnego
|
EP3272343B1
(en)
|
2011-04-29 |
2020-02-12 |
Grünenthal GmbH |
Tapentadol for preventing and treating depression and anxiety
|
US8609088B2
(en)
|
2011-05-10 |
2013-12-17 |
Regents Of The University Of Minnesota |
Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
|
WO2012174481A1
(en)
|
2011-06-15 |
2012-12-20 |
Nerve Access, Inc. |
Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
|
US9402877B2
(en)
|
2011-11-04 |
2016-08-02 |
Xion Pharmaceuticals Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
US10813897B2
(en)
|
2011-12-27 |
2020-10-27 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
US11213501B2
(en)
|
2011-12-27 |
2022-01-04 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
US9962391B2
(en)
|
2011-12-27 |
2018-05-08 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
US11213500B2
(en)
|
2011-12-27 |
2022-01-04 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
US9468599B2
(en)
|
2011-12-27 |
2016-10-18 |
Cmpd Licensing, Llc |
Composition and method for compounded therapy
|
CA2856451A1
(en)
*
|
2012-01-05 |
2013-07-11 |
Beech Tree Labs, Inc. |
Method of treating pain by administration of nerve growth factor
|
US9707414B2
(en)
|
2012-02-14 |
2017-07-18 |
Rainbow Medical Ltd. |
Reflectance-facilitated ultrasound treatment and monitoring
|
US9308163B2
(en)
|
2012-02-15 |
2016-04-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of treating and preventing diseases and disorders of the central nervous system
|
CA3133302A1
(en)
|
2012-07-20 |
2014-01-23 |
Taiga Biotechnologies, Inc. |
Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
|
ES2442242B1
(es)
*
|
2012-08-09 |
2014-11-25 |
Biotechnology Institute, I Mas D, S.L. |
Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
|
US9770593B2
(en)
|
2012-11-05 |
2017-09-26 |
Pythagoras Medical Ltd. |
Patient selection using a transluminally-applied electric current
|
CN107334525B
(zh)
|
2012-11-05 |
2019-10-08 |
毕达哥拉斯医疗有限公司 |
受控组织消融
|
ES2731725T3
(es)
*
|
2012-11-28 |
2019-11-18 |
Nektar Therapeutics |
Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada
|
US9050330B2
(en)
*
|
2012-12-06 |
2015-06-09 |
Jose C. Ramon-de-Jesus |
Method, composition and kit for treating frequent headaches
|
US10639439B2
(en)
|
2013-01-30 |
2020-05-05 |
Midwest Pharmaceuticals, Llc |
Smokeless THC and administration method thereof
|
WO2014130581A1
(en)
*
|
2013-02-20 |
2014-08-28 |
Questcor Pharmaceuticals, Inc. |
Acth for treatment of migraine headache
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
US9365825B2
(en)
|
2013-03-11 |
2016-06-14 |
Taiga Biotechnologies, Inc. |
Expansion of adult stem cells in vitro
|
WO2014144632A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Human pac1 antibodies
|
CN115120746A
(zh)
|
2013-05-15 |
2022-09-30 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
US20150086616A1
(en)
*
|
2013-09-20 |
2015-03-26 |
Steven Lehrer |
Method for the prevention and treatment of alzheimer's disease
|
US11833177B2
(en)
|
2013-12-20 |
2023-12-05 |
Seed Health, Inc. |
Probiotic to enhance an individual's skin microbiome
|
US11826388B2
(en)
|
2013-12-20 |
2023-11-28 |
Seed Health, Inc. |
Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
|
US11839632B2
(en)
|
2013-12-20 |
2023-12-12 |
Seed Health, Inc. |
Topical application of CRISPR-modified bacteria to treat acne vulgaris
|
US11969445B2
(en)
|
2013-12-20 |
2024-04-30 |
Seed Health, Inc. |
Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
UA123759C2
(uk)
|
2014-03-21 |
2021-06-02 |
Тева Фармасьютікалз Інтернешнл Гмбх |
Застосування моноклонального антитіла, яке інгібує шлях пов'язаного з геном кальциноніну пептиду (cgrp), для лікування або зниження частоти випадків мігренозного головного болю у суб'єкта
|
EP3139853B1
(en)
|
2014-05-07 |
2018-12-19 |
Pythagoras Medical Ltd. |
Controlled tissue ablation apparatus
|
EP3154533A4
(en)
*
|
2014-06-16 |
2018-01-10 |
Loewi LLC |
Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
|
EP3194435A1
(en)
|
2014-09-15 |
2017-07-26 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
JP6607509B2
(ja)
*
|
2014-10-01 |
2019-11-20 |
オキシトーン バイオサイエンス ビー.ブイ. |
分娩制御物質を含有する口腔内崩壊性固形医薬投与単位
|
EP3200764B1
(en)
*
|
2014-10-01 |
2020-07-22 |
Oxytone Bioscience B.V. |
Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
|
JP6873906B2
(ja)
|
2014-10-20 |
2021-05-19 |
オイスター ポイント ファーマ インコーポレイテッド |
眼の病状の治療方法
|
US10388407B2
(en)
|
2014-10-21 |
2019-08-20 |
uBiome, Inc. |
Method and system for characterizing a headache-related condition
|
CA2962466C
(en)
|
2014-10-21 |
2023-01-10 |
uBiome, Inc. |
Method and system for microbiome-derived diagnostics and therapeutics
|
CN107106792B
(zh)
|
2014-11-19 |
2020-08-18 |
奥普蒂诺斯公司 |
经鼻给药
|
EP3226972A4
(en)
*
|
2014-12-01 |
2018-08-08 |
Achelios Therapeutics, Inc. |
Methods and compositions for treating migraine and conditions associated with pain
|
KR20180023884A
(ko)
|
2015-01-07 |
2018-03-07 |
트라이제미나 인코퍼레이티드 |
마그네슘-함유 옥시토신 제제 및 사용 방법
|
US9937223B2
(en)
|
2015-01-30 |
2018-04-10 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9744239B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9750785B2
(en)
|
2015-01-30 |
2017-09-05 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9687526B2
(en)
|
2015-01-30 |
2017-06-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9744209B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9925233B2
(en)
|
2015-01-30 |
2018-03-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9522918B2
(en)
|
2015-02-12 |
2016-12-20 |
Neonc Technologies, Inc. |
Pharmaceutical compositions comprising perillyl alcohol derivatives
|
WO2016140063A1
(ja)
*
|
2015-03-04 |
2016-09-09 |
栄研化学株式会社 |
オキシトシンの高感度測定法
|
WO2016168760A1
(en)
|
2015-04-16 |
2016-10-20 |
Alder Biopharmaceuticals, Inc. |
Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
|
US10383685B2
(en)
|
2015-05-07 |
2019-08-20 |
Pythagoras Medical Ltd. |
Techniques for use with nerve tissue
|
US11207461B2
(en)
|
2015-07-30 |
2021-12-28 |
Anoop U. R |
Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
|
US11213480B1
(en)
|
2015-08-06 |
2022-01-04 |
Hikma Pharmaceuticals International Limited |
Phenylephrine hydrochloride ready-to-use solution
|
US10335406B2
(en)
|
2015-10-01 |
2019-07-02 |
Elysium Therapeutics, Inc. |
Opioid compositions resistant to overdose and abuse
|
US9808452B2
(en)
|
2015-10-01 |
2017-11-07 |
Elysium Therapeutics, Inc. |
Polysubunit opioid prodrugs resistant to overdose and abuse
|
EP3390447A1
(en)
|
2015-12-15 |
2018-10-24 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
CA3020179A1
(en)
*
|
2016-04-12 |
2017-10-19 |
Trigemina, Inc. |
Magnesium-containing oxytocin formulations and methods of use
|
JP7171439B2
(ja)
|
2016-04-15 |
2022-11-15 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ii型を処置するための遺伝子療法
|
WO2017181031A2
(en)
|
2016-04-15 |
2017-10-19 |
Alder Biopharmaceuticals, Inc. |
Anti-pacap antibodies and uses thereof
|
US11678932B2
(en)
|
2016-05-18 |
2023-06-20 |
Symap Medical (Suzhou) Limited |
Electrode catheter with incremental advancement
|
US10392434B2
(en)
|
2016-09-23 |
2019-08-27 |
Teva Pharmaceuticals International Gmbh |
Treating refractory migraine
|
EP3687375A4
(en)
*
|
2016-11-21 |
2022-01-19 |
Psomagen, Inc. |
METHOD AND SYSTEM FOR CHARACTERIZING A HEADACHE RELATED CONDITION
|
WO2018102412A1
(en)
|
2016-11-30 |
2018-06-07 |
Neonc Technologies, Inc. |
A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
|
EP4242298A2
(en)
|
2016-12-02 |
2023-09-13 |
Taiga Biotechnologies, Inc. |
Nanoparticle formulations
|
US10932711B2
(en)
|
2017-02-27 |
2021-03-02 |
Payman Sadeghi |
Method and system for neurohydrodissection
|
US10456419B2
(en)
|
2017-02-27 |
2019-10-29 |
Payman Sadeghi |
Method for treating migraine headaches
|
AU2018234911B2
(en)
|
2017-03-17 |
2024-04-18 |
Elysium Therapeutics, Inc. |
Polysubunit opioid prodrugs resistant to overdose and abuse
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
US11819539B2
(en)
|
2017-09-22 |
2023-11-21 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating Mucopolysaccharidosis type II
|
KR20200110362A
(ko)
*
|
2018-01-12 |
2020-09-23 |
암젠 인크 |
Pac1 항체 및 이의 용도
|
DK3749291T3
(da)
|
2018-02-08 |
2024-04-08 |
Univ Southern California |
Fremgangsmåder til permeabilisering af blod-hjerne-barrieren
|
WO2020061584A1
(en)
*
|
2018-09-21 |
2020-03-26 |
Msb Holdings, Inc. |
Taste-masked dosage forms
|
US11135379B2
(en)
|
2019-02-15 |
2021-10-05 |
Bn Intellectual Properties, Inc. |
Method of delivering pharmaceutical products
|
CA3132082A1
(en)
|
2019-03-14 |
2020-09-17 |
Om Pharma Sa |
Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
|
WO2021016190A1
(en)
*
|
2019-07-19 |
2021-01-28 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Compositions and methods for modulating drug-use disorders
|
US11364225B2
(en)
*
|
2019-08-21 |
2022-06-21 |
Bn Intellectual Properties, Inc. |
Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
|
BR112022003687A2
(pt)
*
|
2019-08-29 |
2022-05-24 |
Univ New York |
Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina
|
US20240100120A1
(en)
*
|
2019-10-11 |
2024-03-28 |
Board Of Regents, The University Of Taxas System |
Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
|
AU2021211012A1
(en)
|
2020-01-24 |
2022-08-25 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
JP2024518860A
(ja)
*
|
2020-08-10 |
2024-05-08 |
ジロパ・インコーポレイテッド |
局所送達用組成物及び方法
|
WO2023146579A1
(en)
*
|
2022-01-27 |
2023-08-03 |
Belnap Pharmaceuticals, Llc |
Methods of treatment using oxytocin
|